New ‘exclusivity board’ at US FDA will oversee determinations for drugs
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has established an “exclusivity board” in its Center for Drug Evaluation and Research to provide oversight and recommendations regarding exclusivity determinations made by the centre, with a primary focus on clarity and consistency of decisions1.